Amer Zeidan was appointed as the inaugural Chief of the Division of Hematologic Malignancies at Yale Cancer Center

Yale Cancer Center shared on LinkedIn:

“We are pleased to announce that Amer Zeidan was appointed as the inaugural Chief of the Division of Hematologic Malignancies at Yale Cancer Center.

In 2014, Dr. Zeidan joined the Yale faculty as an Assistant Professor of Medicine (Hematology) and was promoted to Associate Professor in 2019. He has more than 330 peer-reviewed publications, is the principal investigator on numerous phase II and III clinical trials, and has rapidly become a leading clinical expert and trialist in the areas of acute myeloid leukemia and myelodysplastic syndromes.

Dr. Zeidan is an accomplished clinician, clinical and translational investigator, mentor, and educator, and he is passionate about making a difference for patients with hematologic malignancies. Dr. Zeidan is also committed to building a world-class hematologic malignancy program at Yale Cancer Center and Smilow Cancer Hospital.

Please join us in congratulating Dr. Zeidan!”

Further details.
Source: Yale Cancer Center/LinkedIn

Amer Zeidan is an Associate Professor of Medicine (Hematology) at Yale University. He is also the medical director of Hematology Early Therapeutics Research, the leader of the Myeloid Malignancies DART (Disease Aligned Research Team), and the director of Continuing Medical Education (CME) at the Hematology division and chairs the Protocol Review Committee (PRC) at Yale Cancer Center. Dr. Zeidan is a well-known leukemia researcher with a special focus on targeted therapies and immunotherapy for myeloid malignancies, and a social media influencer in the field of blood cancer.